Cargando…
Immuno(T)herapy for age‐related diseases
During the last decade, the stimulation of T‐cell function by the blockage of immunosuppressive checkpoints has experienced an outstanding impact in the treatment of cancer. Development of the chimeric antigen receptor T‐cell technology has also emerged as a powerful alternative for patients sufferi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832825/ https://www.ncbi.nlm.nih.gov/pubmed/36373340 http://dx.doi.org/10.15252/emmm.202216301 |
Sumario: | During the last decade, the stimulation of T‐cell function by the blockage of immunosuppressive checkpoints has experienced an outstanding impact in the treatment of cancer. Development of the chimeric antigen receptor T‐cell technology has also emerged as a powerful alternative for patients suffering from oncological processes, especially those affected by hematological neoplasms. Recent evidence suggest that the use of immunotherapy could be extended to non‐oncological diseases and could be especially relevant for age‐associated disorders, opening exciting therapeutic options for a wide range of diseases of the elderly. Here we comment on the emergence of T‐cell‐based immunotherapies as feasible approaches that could revolutionize the future of GeroScience. |
---|